Effectiveness of transdermal nicotine patch in premenopausal female smokers is moderated by within-subject severity of negative affect and physical symptoms.

Autor: Chai SH; Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA., Leventhal AM; Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA.; Department of Psychology, University of Southern California, Los Angeles, CA, USA., Kirkpatrick MG; Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA., Eisenlohr-Moul TA; Department of Psychiatry, University of Illinois Chicago, Chicago, IL, USA., Rapkin AJ; Department of Obstetrics and Gynecology, Center for the Health Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., D'Orazio L; Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA., Pang RD; Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA. rpang@usc.edu.
Jazyk: angličtina
Zdroj: Psychopharmacology [Psychopharmacology (Berl)] 2020 Jun; Vol. 237 (6), pp. 1737-1744. Date of Electronic Publication: 2020 Mar 10.
DOI: 10.1007/s00213-020-05494-z
Abstrakt: Rationale: Nicotine patches may be less effective in female compared with male smokers. However, it is unknown if negative affect and physical symptoms influence transdermal nicotine patch-related effects on smoking behaviors.
Methods: Eighty-one acutely tobacco-abstinent premenopausal female smokers attended three counter-balanced experimental sessions across the menstrual cycle (early follicular, late follicular, and mid-luteal) and were randomized to patch condition (nicotine [21 mg] vs. placebo [0 mg] transdermal patch). Negative affect and physical symptoms were assessed prior to patch administration. The patch was removed 5 h post-administration, and participants completed a smoking reinstatement task. Multilevel linear models tested associations of patch condition, negative affect and physical symptoms, and their interaction on smoking behavior.
Results: There was a significant patch condition × Negative Affect and Pain symptoms interaction on the number of cigarettes smoked (p < 0.05). When Negative Affect and Pain were lower-than-usual, females administered a nicotine patch smoked significantly fewer cigarettes than females administered a placebo patch (p < .05), but there were no significant patch differences when Negative Affect and Pain were higher-than-usual. There was also a significant patch condition × Negative Affect interaction on time delay. The effects of patch condition on time delay to smoking were greater during sessions in which Negative Affect was higher-than-usual.
Conclusions: Results suggest that among female smokers transdermal nicotine patch effectiveness may interact with negative affect and pain. Understanding and considering female-specific factors that may impact the efficacy of one of the most commonly used cessation medications is important for improving smoking cessation in female smokers.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje